Burden of COVID-19 disease in Kurdistan province in west of Iran using disability-adjusted life years.
COVID‐19
Iran
burden of disease
disability‐adjusted life years
years of life lost
Journal
Health science reports
ISSN: 2398-8835
Titre abrégé: Health Sci Rep
Pays: United States
ID NLM: 101728855
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
02
10
2022
revised:
08
01
2023
accepted:
02
03
2023
entrez:
27
3
2023
pubmed:
28
3
2023
medline:
28
3
2023
Statut:
epublish
Résumé
During the coronavirus disease 2019 (COVID-19) pandemic, about seven million people were infected with the disease, of which more than 133,000 died. Health policymakers need to know the extent and magnitude of the disease burden to decide on how much to allocate resources for disease control. The results of this investigation could be helpful in this field. We used the secondary data released by the Kurdistan University of Medical Sciences between February 2020 to October 2021 to estimate the age-sex standardized disability-adjusted life years (DALY) by the sum of the years of life lived with disability (YLD) and the years of life lost (YLL). We also applied the local and specific values of the disease utility in the calculations. The total DALY was estimated at 23316.5 and 1385.5 per 100,000 populations The YLD and YLL constituted 1% and 99% of the total DALY, respectively. The DALY per 100,000 populations was highest in the men and people aged more than 65 years, but the prevalence was the highest in people under the age of 40. Compared to the findings of the "burden of disease study 2019," the burden of COVID-19 in Iran is ranked first and eighth among communicable and noncommunicable diseases, respectively. Although the disease affects all groups, the elderly suffer the most from it. Given the very high YLL of COVID-19, the best strategy to reduce the burden of COVID-19 in subsequent waves should be to focus on preventing infection in the elderly population and reducing mortality.
Sections du résumé
Background and Aims
UNASSIGNED
During the coronavirus disease 2019 (COVID-19) pandemic, about seven million people were infected with the disease, of which more than 133,000 died. Health policymakers need to know the extent and magnitude of the disease burden to decide on how much to allocate resources for disease control. The results of this investigation could be helpful in this field.
Methods
UNASSIGNED
We used the secondary data released by the Kurdistan University of Medical Sciences between February 2020 to October 2021 to estimate the age-sex standardized disability-adjusted life years (DALY) by the sum of the years of life lived with disability (YLD) and the years of life lost (YLL). We also applied the local and specific values of the disease utility in the calculations.
Results
UNASSIGNED
The total DALY was estimated at 23316.5 and 1385.5 per 100,000 populations The YLD and YLL constituted 1% and 99% of the total DALY, respectively. The DALY per 100,000 populations was highest in the men and people aged more than 65 years, but the prevalence was the highest in people under the age of 40.
Conclusions
UNASSIGNED
Compared to the findings of the "burden of disease study 2019," the burden of COVID-19 in Iran is ranked first and eighth among communicable and noncommunicable diseases, respectively. Although the disease affects all groups, the elderly suffer the most from it. Given the very high YLL of COVID-19, the best strategy to reduce the burden of COVID-19 in subsequent waves should be to focus on preventing infection in the elderly population and reducing mortality.
Identifiants
pubmed: 36970642
doi: 10.1002/hsr2.1154
pii: HSR21154
pmc: PMC10033847
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1154Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Bull World Health Organ. 2021 Feb 01;99(2):112-124
pubmed: 33551505
Iran J Med Sci. 2020 Jul;45(4):231-232
pubmed: 32801412
Aging Clin Exp Res. 2020 Jul;32(7):1189-1194
pubmed: 32458356
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
J Korean Med Sci. 2020 Aug 17;35(32):e300
pubmed: 32808515
Health Sci Rep. 2023 Mar 22;6(3):e1154
pubmed: 36970642
Int J Environ Res Public Health. 2020 Jun 13;17(12):
pubmed: 32545827
PLoS One. 2021 Jul 29;16(7):e0255534
pubmed: 34324556
Science. 2020 Jul 24;369(6502):413-422
pubmed: 32532802
Lancet Public Health. 2020 May;5(5):e253
pubmed: 32220653
Arch Public Health. 2020 May 29;78:47
pubmed: 32501409
J Ment Health. 2021 Apr;30(2):148-155
pubmed: 33689546
Int J Mol Epidemiol Genet. 2021 Dec 15;12(6):120-125
pubmed: 35126835
BMJ Open. 2021 May 18;11(5):e048822
pubmed: 34006559
BMC Public Health. 2020 Nov 2;20(1):1636
pubmed: 33138798
BMC Infect Dis. 2021 May 20;21(1):459
pubmed: 34016041
Qual Life Res. 2021 May;30(5):1389-1405
pubmed: 33389523
BMC Public Health. 2021 Oct 9;21(1):1827
pubmed: 34627228
BMC Infect Dis. 2021 Apr 12;21(1):343
pubmed: 33845774
J Med Econ. 2021 Jan-Dec;24(1):308-317
pubmed: 33555956
Front Psychiatry. 2020 Jul 08;11:668
pubmed: 32733299
EClinicalMedicine. 2021 Mar;33:100771
pubmed: 33681730
Front Public Health. 2021 Aug 17;9:686700
pubmed: 34485216
PeerJ. 2022 Apr 7;10:e13219
pubmed: 35415012
J Am Coll Emerg Physicians Open. 2022 Sep 05;3(5):e12811
pubmed: 36090004
J Formos Med Assoc. 2021 Jun;120 Suppl 1:S106-S117
pubmed: 34119392
Soc Psychiatry Psychiatr Epidemiol. 2021 Jan;56(1):165-167
pubmed: 33034669
Value Health. 2021 May;24(5):615-624
pubmed: 33933229
J Stroke Cerebrovasc Dis. 2020 Sep;29(9):105089
pubmed: 32807484
Anesth Analg. 2020 Jul;131(1):86-92
pubmed: 32243287
BMC Health Serv Res. 2021 Feb 11;21(1):132
pubmed: 33573650
Dtsch Arztebl Int. 2021 Mar 5;118(9):145-151
pubmed: 33958032
Indian J Public Health. 2022 Jul-Sep;66(3):239-244
pubmed: 36149098
J Korean Med Sci. 2020 Jun 01;35(21):e199
pubmed: 32476305
J Infect Chemother. 2021 Oct;27(10):1482-1488
pubmed: 34244054
Eur J Epidemiol. 2022 Oct;37(10):1035-1047
pubmed: 35951278
Arch Iran Med. 2020 Jul 01;23(7):455-461
pubmed: 32657596
Popul Health Metr. 2003 Apr 14;1(1):4
pubmed: 12773212
Health Soc Care Community. 2022 Jul;30(4):1550-1561
pubmed: 34219320
J Clin Epidemiol. 2022 Feb;142:54-59
pubmed: 34715312
Head Neck. 2020 Jul;42(7):1629-1633
pubmed: 32342570
Sci Rep. 2022 Feb 14;12(1):2454
pubmed: 35165362
Rev Peru Med Exp Salud Publica. 2022 Jul-Sep;39(3):281-291
pubmed: 36478161
Int J Public Health. 2021 Mar 05;66:619011
pubmed: 34744580
Med J Aust. 2020 Oct;213(8):342-344.e1
pubmed: 32946607
Eur Rev Med Pharmacol Sci. 2021 Sep;25(17):5529-5541
pubmed: 34533803
Nurs Open. 2021 Jan;8(1):72-79
pubmed: 32904939